{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:17:44Z","timestamp":1779279464150,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11102-026-01664-y","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:50:46Z","timestamp":1774425046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly"],"prefix":"10.1007","volume":"29","author":[{"given":"Ellie","family":"Edlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiul","family":"Muquit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Shivane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"5","key":"1664_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT et al (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173(5):655\u2013664","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1664_CR2","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769\u20134775","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1664_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"19","key":"1664_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A (2025) Acromegaly N Engl J Med 393(19):1926\u20131939","journal-title":"Acromegaly N Engl J Med"},{"issue":"4068","key":"1664_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.179.4068.77","volume":"179","author":"P Brazeau","year":"1973","unstructured":"Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068):77\u201379. https:\/\/doi.org\/10.1126\/science.179.4068.77","journal-title":"Science"},{"issue":"4","key":"1664_CR6","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ et al (2014) Tumor shrinkage with lanreotide Autogel 120\u00a0mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1664_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1530\/EJE-15-0215","volume":"173","author":"SJ Neggers","year":"2015","unstructured":"Neggers SJ et al (2015) Lanreotide Autogel 120\u00a0mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol 173(3):313\u2013323","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1664_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"1664_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Reviews Endocrinol 21(11):718\u2013737","journal-title":"Nat Reviews Endocrinol"},{"issue":"11","key":"1664_CR10","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1664_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cen.14790","volume":"98","author":"C Papaioannou","year":"2023","unstructured":"Papaioannou C, Druce M (2023) Preoperative medical treatments and surgical approaches for acromegaly: a systematic review. Clin Endocrinol (Oxf) 98(1):14\u201331","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1664_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"},{"issue":"11","key":"1664_CR13","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1210\/jc.2009-2556","volume":"95","author":"AF Daly","year":"2010","unstructured":"Daly AF et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373\u2013E383","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1664_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1530\/ERC-15-0320","volume":"22","author":"L Rostomyan","year":"2015","unstructured":"Rostomyan L et al (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22(5):745\u2013757","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1664_CR15","doi-asserted-by":"publisher","first-page":"e2247","DOI":"10.1210\/clinem\/dgaa040","volume":"105","author":"P Marques","year":"2020","unstructured":"Marques P et al (2020) Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J Clin Endocrinol Metab 105(6):e2247\u2013e2260","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1664_CR16","doi-asserted-by":"publisher","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","volume":"97","author":"HS Chahal","year":"2012","unstructured":"Chahal HS et al (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411\u2013E1420","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1664_CR17","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/onc.2014.50","volume":"34","author":"I Tuominen","year":"2015","unstructured":"Tuominen I et al (2015) AIP inactivation leads to pituitary tumorigenesis through defective Galphai-cAMP signaling. Oncogene 34(9):1174\u20131184","journal-title":"Oncogene"},{"issue":"2","key":"1664_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/EJE-16-0620","volume":"176","author":"E Ritvonen","year":"2017","unstructured":"Ritvonen E et al (2017) Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 176(2):243\u2013252","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1664_CR19","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1002\/ijc.33268","volume":"147","author":"EM Bogner","year":"2020","unstructured":"Bogner EM et al (2020) miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int J Cancer 147(12):3523\u20133538","journal-title":"Int J Cancer"},{"issue":"2","key":"1664_CR20","doi-asserted-by":"publisher","first-page":"e0117107","DOI":"10.1371\/journal.pone.0117107","volume":"10","author":"J Denes","year":"2015","unstructured":"Denes J et al (2015) Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS ONE 10(2):e0117107","journal-title":"PLoS ONE"},{"issue":"1","key":"1664_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000322787","volume":"94","author":"J de Kasuki","year":"2011","unstructured":"de Kasuki J, PL et al (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94(1):39\u201348","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1664_CR22","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1530\/ERC-12-0020","volume":"19","author":"L Kasuki","year":"2012","unstructured":"Kasuki L et al (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25\u2013L29","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1664_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41574-023-00949-7","volume":"20","author":"M Korbonits","year":"2024","unstructured":"Korbonits M et al (2024) Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases. Nat Rev Endocrinol 20(5):290\u2013309","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1664_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-18-0254","volume":"180","author":"F Bonneville","year":"2019","unstructured":"Bonneville F et al (2019) MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis. Eur J Endocrinol 180(3):155\u2013164","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1664_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1046\/j.1365-2265.2003.01741.x","volume":"58","author":"T Lucas","year":"2003","unstructured":"Lucas T et al (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58(4):471\u2013481","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1664_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1530\/ERC-12-0322","volume":"20","author":"ML Jaffrain-Rea","year":"2013","unstructured":"Jaffrain-Rea ML et al (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20(5):753\u2013766","journal-title":"Endocr Relat Cancer"},{"key":"1664_CR27","doi-asserted-by":"crossref","unstructured":"Chahal HS et al (2011) Somatostatin analogue treatment increases AIP protein expression in somatotroph tumours from patients with acromegaly and in GH3 cells in vitro. in Horm Res Paediatr 76(Suppl. 1), pp. 111\u2013112","DOI":"10.1159\/000329195"},{"issue":"2","key":"1664_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/ERC-14-0305","volume":"22","author":"I Potorac","year":"2015","unstructured":"Potorac I et al (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169\u2013177","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1664_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","volume":"23","author":"I Potorac","year":"2016","unstructured":"Potorac I et al (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871\u2013881","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1664_CR30","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/jc.2010-0573","volume":"95","author":"M Puig-Domingo","year":"2010","unstructured":"Puig-Domingo M et al (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973\u20134978","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1664_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72\u201378","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1664_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","volume":"52","author":"A Heck","year":"2016","unstructured":"Heck A et al (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333\u2013343","journal-title":"Endocrine"},{"issue":"1","key":"1664_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12020-015-0816-2","volume":"53","author":"A Heck","year":"2016","unstructured":"Heck A et al (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327\u2013330","journal-title":"Endocrine"},{"issue":"1","key":"1664_CR34","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1038\/s41598-019-50639-6","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C et al (2019) Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies. Sci Rep 9(1):14070","journal-title":"Sci Rep"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01664-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:01:29Z","timestamp":1779278489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01664-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval, Good Clinical Practice guidelines, and all local regulatory requirements. The study was approved by the local research ethics committee initially as single centre study (NCT00225134, EudraCT number: 2005-004300-36) and subsequently as part of the PRIMARYS study (Clinical trials.gov NCT00690898, EudraCT number 2007-000155-34).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}